Micro
Aftermath
Archived
Pfizer CFO Dave Denton Steps Down
Activity declining — narrative losing relevance.
Score
0.3
Velocity
▲ 0.0
Articles
5
Sources
2
Sentiment Timeline
Event Timeline
Related Articles
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in …
Nasdaq
·
Jun 28, 2026
Nike Names Pfizer's David Denton CFO, Succeeding Matthew Friend; Sees Q4 To Include Tariff Benefit
Nasdaq
·
Jun 24, 2026
Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15
Yahoo Finance
·
Jun 22, 2026
🤖
AI Overview
What happened: Pfizer's CFO Dave Denton announced his departure on August 15 to pursue a new opportunity in the consumer goods industry. Pfizer appointed Cecile Guegan, currently senior vice president of finance, as interim CFO. This news comes as Pfizer is considered one of the most undervalued NYSE stocks.
Market impact: Pfizer's stock fell 2.74% to $25.21 following the announcement, as investors focused on the 2026 outlook and leadership continuity. The CFO transition may test confidence in Pfizer's long-term guidance and strategy.
What to watch next: Pfizer's Q2 earnings report on July 28 will provide insight into the company's financial health and guidance under interim CFO Guegan. Additionally, investors will closely monitor any updates on Pfizer's 2026 outlook during the Q2 earnings call.
Market impact: Pfizer's stock fell 2.74% to $25.21 following the announcement, as investors focused on the 2026 outlook and leadership continuity. The CFO transition may test confidence in Pfizer's long-term guidance and strategy.
What to watch next: Pfizer's Q2 earnings report on July 28 will provide insight into the company's financial health and guidance under interim CFO Guegan. Additionally, investors will closely monitor any updates on Pfizer's 2026 outlook during the Q2 earnings call.
AI Overview as of Jun 22, 2026
Timeline
Last UpdatedJun 18, 2026